id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-N-1819-0008,FDA,FDA-2020-N-1819,Ref 1 - Economic Analysis RE Certain Requirements Regarding Prescription Drug Marketing,Supporting & Related Material,Background Material,2022-04-12T04:00:00Z,2022,4,,,2022-04-12T12:47:19Z,,0,0,0900006485010431
FDA-2020-N-1819-0001,FDA,FDA-2020-N-1819,Certain Requirements Regarding Prescription Drug Marketing,Proposed Rule,Notice of Proposed Rulemaking (NPRM),2022-02-04T05:00:00Z,2022,2,2022-02-04T05:00:00Z,2022-04-06T03:59:59Z,2022-04-07T01:00:49Z,2022-01927,0,0,0900006484f54a12